Allotex Accelerates into Commercial Phase and appoints Michael Mrochen as new CEO

Allotex is advancing a natural, biologic approach to vision correction announced global commercial rollout under the new leadership of Michael Mrochen.

BOSTON, MA, UNITED STATES, May 1, 2025 /EINPresswire.com/ -- Allotex, a biotech and medical device company advancing a natural, biologic approach to vision correction, today announced major progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and Australia, the company is actively executing a controlled market launch and preparing for expansion into additional regions. Regulatory efforts are progressing, including plans to submit an Investigational Device Exemption (IDE) in the United States in the second quarter of 2025 to develop further market access.

To lead this next phase of commercial growth, Michael Mrochen, PhD, has been appointed as Chief Executive Officer. A co-founder of Allotex and a globally recognized innovator in ophthalmology, Dr. Mrochen brings deep scientific expertise and commercial acumen to the role.

“I’m honored to lead Allotex as we bring this breakthrough technology to more people,” said Dr. Mrochen. “Our platform restores vision naturally—without glasses, without invasive surgery, and without compromising future treatment options.”

Dr. David Muller, who has served as CEO since Allotex’s founding, is supporting the planned transition and will remain with the company as Scientific Advisor.

“Michael is the right person to lead Allotex into its next chapter,” said Dr. Muller. “He’s strategic, experienced, and passionate about helping people see better.”

The Board of Directors expressed its gratitude to Dr. Muller for his leadership and endorsed Dr. Mrochen’s appointment to guide the company through its commercial scaling and strategic evolution.

A New Option for Clearer Vision Without Glasses
Allotex has developed the world’s first natural, human collagen-based eye implant designed to help people over 40 restore their near vision—without relying on reading glasses. The implant is placed just beneath the surface of the eye in a quick, outpatient procedure that takes about 10 minutes. Made from natural human collagen—not synthetic material—the implant is flexible, meaning it can be adjusted or removed if needed.

About Dr. Michael Mrochen
Michael Mrochen, PhD, is a globally recognized entrepreneur and innovation leader in ophthalmology, with a 30-year track record of transforming scientific breakthroughs into commercially successful technologies. He has founded and led multiple ventures in the vision care field, guided several to strategic exits, and played a key role in advancing products now used by eye care professionals worldwide. His contributions have earned recognition from leading ophthalmic societies, and he has been named multiple times as one of the most influential people in ophthalmology. He is widely considered a driving force in the future of vision correction.

About Allotex
Allotex is a biotech and medical device company developing natural solutions for vision correction. Its first product is a small implant made from human collagen—a substance naturally found in the eye. This implant helps people regain their near vision as they age, eliminating the need for reading glasses—a condition that affects one-third of the world’s population. Allotex’s approach is minimally invasive, flexible, and designed to feel natural. The company is also actively exploring other vision conditions using its collagen-based platform technology.

With offices in the United States and Europe, Allotex is preparing to expand into additional countries to help more people see clearly—naturally.

Travis Henry
Allotex
info|allotex.com| |info|allotex.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.